Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

ITC Litigation & Section 337

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Blog | March 13, 2014

NDCA denies summary judgment and Daubert motions on lost profits and reasonable royalty; allows patentee's entire market value and comparable license theories

Blog | March 12, 2014

NDCA denies motion to strike reports for inadequate apportionment in lost profits and reasonable royalty; allows testimony on disputed licenses and offer to license

Article | March 07, 2014

Drug Labeling Games: Skinny Labels Getting an FDA Assist

Blog | February 28, 2014

Fed. Cir. Confirms De Novo Review of Claim Construction

Blog | February 21, 2014

No foreseeability exception to doctrine of equivalents

Blog | February 20, 2014

Inurement for 102(g)(2) Does Not Require the Inventor to Expressly Direct Another to Reduce His Invention to Practice

Blog | February 12, 2014

Hatch-Waxman safe harbor expansion continues

Blog | January 27, 2014

NDGA rejects two-supplier market theory for lost profits

Blog | January 17, 2014

EDTX admits plaintiff's EMVR testimony

Blog | January 15, 2014

EDTX allows cost savings approach for royalties, based on cost of entire location network

Blog | January 13, 2014

SDNY grants SJ of no pre-notice damages where plaintiff failed to plead marking

Blog | December 24, 2013

SDNY comments on EMVR's application in pharma context